Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Sells 520,915 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,016,028 shares of the company’s stock after selling 520,915 shares during the period. Cellebrite DI comprises 1.8% of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD’s holdings, making the stock its 18th largest position. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD’s holdings in Cellebrite DI were worth $22,365,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLBT. Quarry LP bought a new stake in shares of Cellebrite DI in the 3rd quarter worth $27,000. Advisors Asset Management Inc. grew its stake in shares of Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after acquiring an additional 1,742 shares in the last quarter. R Squared Ltd bought a new stake in shares of Cellebrite DI in the 4th quarter worth $100,000. Venturi Wealth Management LLC grew its stake in shares of Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI in the 4th quarter worth $234,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Monday. Finally, Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Stock Up 2.7 %

NASDAQ CLBT opened at $17.23 on Wednesday. The firm’s 50-day simple moving average is $21.67 and its two-hundred day simple moving average is $19.72. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The company has a market cap of $3.55 billion, a PE ratio of -12.40, a price-to-earnings-growth ratio of 4.27 and a beta of 1.53.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.